HELM INTELLIGENCEPFE
Preparing your analysis.
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Working on your request
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Investors should consider the mixed signals from Pfizer's financial metrics and market position when assessing potential investment opportunities.
Pfizer Inc has a market capitalization of $158.25B and a current stock price of $27.70, reflecting a slight increase of 0.18% from the previous close of $27.65. The P/E ratio stands at 20.37, while revenue and EPS have declined year-over-year by 1.65% and 3.55%, respectively. The stock's 52-week range is between $23.59 and $29.21.
Some investors point to Pfizer's strong market position within the pharmaceutical industry and its robust pipeline of products, which could drive future revenue growth. The company's ability to maintain a competitive P/E ratio of 20.37 may be appealing in a sector marked by high valuations.
Conversely, concerns arise from Pfizer's year-over-year declines in both revenue and EPS, which may indicate underlying challenges in sustaining growth. Additionally, the current ratio of 1.16 suggests limited short-term liquidity, potentially impacting operational flexibility.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Pfizer Inc has a market capitalization of $158.25B and a current stock price of $27.70, reflecting a slight increase of 0.18% from the previous close of $27.65. The P/E ratio stands at 20.37, while revenue and EPS have declined year-over-year by 1.65% and 3.55%, respectively. The stock's 52-week range is between $23.59 and $29.21.
Conversely, concerns arise from Pfizer's year-over-year declines in both revenue and EPS, which may indicate underlying challenges in sustaining growth. Additionally, the current ratio of 1.16 suggests limited short-term liquidity, potentially impacting operational flexibility.
Some investors point to Pfizer's strong market position within the pharmaceutical industry and its robust pipeline of products, which could drive future revenue growth. The company's ability to maintain a competitive P/E ratio of 20.37 may be appealing in a sector marked by high valuations.
Some investors point to Pfizer's strong market position within the pharmaceutical industry and its robust pipeline of products, which could drive future revenue growth. The company's ability to maintain a competitive P/E ratio of 20.37 may be appealing in a sector marked by high valuations. Conversely, concerns arise from Pfizer's year-over-year declines in both revenue and EPS, which may indicate underlying challenges in sustaining growth. Additionally, the current ratio of 1.16 suggests limited short-term liquidity, potentially impacting operational flexibility.
Pfizer Inc has a market capitalization of $158.25B and a current stock price of $27.70, reflecting a slight increase of 0.18% from the previous close of $27.65. The P/E ratio stands at 20.37, while revenue and EPS have declined year-over-year by 1.65% and 3.55%, respectively. The stock's 52-week range is between $23.59 and $29.21.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for PFE at helmterminal.dev/analyze/PFE, updated continuously during US market hours. No signup required.